The NCITA Repository Unit has commenced a new partnership with University of Oxford team to support the Phase 1 ARCADIAN trial. The trial will assess a combination therapy of hypoxia-modifying drug atovaquone with chemoradiotherapy in patients with locally advanced non-small cell lung cancer.
Research has shown that tumour hypoxia, resulting from rapid tumour growth and depletion of the oxygen supply in areas of the tumour, reduces the responsiveness of tumours to radiation and chemotherapy. The Arcadian Trial, led by Professor Geoff Higgins at Oxford, aims to establish the maximum tolerated dose of hypoxia-modifying atovaquone that can safely be combined with radiotherapy.
Preclinical studies have shown that atovaquone can significantly reduce tumour hypoxia in xenograft models at clinically relevant doses. However, no hypoxia modifying treatments are currently in widespread clinical use. A major barrier to developing hypoxia-modifying agents has been a lack of validated hypoxia imaging biomarkers, resulting in an inability to accurately stratify patients in clinical studies. The ARCADIAN trial will include important translational endpoints to identify such biomarkers. The NCITA Repository Unit will support the secure storage and sharing of patient datasets between clinical sites.
The ARCADIAN phase 1 study is sponsored by the University of Oxford and is funded by Cancer Research UK (ref C34326/A27515).
The trial will be open for recruitment shortly.
About the NCITA Repository Unit
The NCITA Repository Unit provides an image repository and data management service for secure storage of imaging biomarker trial data and sharing of anonymised datasets between trials sites in multicentre clinical trials. The repository is based on a comprehensive platform for secure archiving, processing and sharing of research imaging data previously developed by the CRUK Cancer Imaging Centres (CIC) initiative.
If you are interested to find out more about the NCITA Repository Unit support services for clinical research studies, please contact us at email@example.com